Masakazu Iizuka

Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Y. Eguchi, A. Nakajima, R. Loomba, 2021, Alimentary pharmacology & therapeutics.